Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, t...
Shanghai Haohai Biological Tech files HKEX next-day disclosure return on share repurchase for cancellation
Shanghai Haohai Biological files HKEX next-day return disclosing share buyback for cancellation
Shanghai Haohai Biological Tech files HKEX next-day return disclosing share cancellation after repurchase at HKD 22.17
Shanghai Haohai Says Controlling Shareholder Released on Bail in Unrelated Insider Trading Case
Bin Hui Biotechnology Submits Listing Application to Hong Kong Stock Exchange
"Performance" HAOHAI BIOTEC's annual net profit is 251 million RMB, down 40.3%, with a final dividend of 0.60 RMB